A101-AB-MMAE NDC

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameA101-AB-MMAE NDC

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload +[4]

Mechanisms of ActionAnti-MesothelinTubulin inhibitors

TargetsMesothelinTubulin

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomSpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute Astrazeneca Plc HCW Biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesInternational University Of La Rioja University Of Cambridge Astrazeneca Plc +[5]

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A